U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H14O3
Molecular Weight 254.2806
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KETOPROFEN

SMILES

CC(C(O)=O)C1=CC=CC(=C1)C(=O)C2=CC=CC=C2

InChI

InChIKey=DKYWVDODHFEZIM-UHFFFAOYSA-N
InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)

HIDE SMILES / InChI
Molecular Formula C16H14O3
Molecular Weight 254.2806
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2c99853-1268-4998-a44b-2bf0c0b70fd2 https://www.ncbi.nlm.nih.gov/pubmed/9626023 https://www.ncbi.nlm.nih.gov/pubmed/3526298

Ketoprofen is a drug belonging to the family of non-steroidal anti-inflammatory drugs. Ketoprofen, was synthesized in France by Rhône-Poulenc chemists in 1967, and introduced in 1973 in France and the United Kingdom for antiinflammatory use. Ketoprofen selectively inhibits isoform-I of cyclo-oxygenase, COX-1. Ketoprofen has shown to be an excellent choice of drug for the treatment of chronic pain in patients with osteoarthritis, rheumatoid arthritis. In addition Ketoprofen is prescribed for management of pain (acute forms of pain, traumatic and post-surgical pain) and also indicated for treatment of primary dysmenorrhea

CNS Activity

CNS Active
3897
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/2079099

Originator

Rhône-Poulenc
45
Curator's Comment: 1967

Approval Year

1986
103
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
 1.9 nM [IC50]
Inhibitor
8146
 27.0 nM [IC50]
Antagonist
2737
 50.0 nM [IC50]
Inhibitor
8146
 0.52 µM [IC50]
Inhibitor
8146
 0.019 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
Keral

Approved Use

Unknown
Primary
Approved
8307
Keral

Approved Use

Unknown
Primary
Approved
8307
Keral

Approved Use

Unknown
Primary
Approved
8307
KETOPROFEN

Approved Use

Ketoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea.

Launch Date

7.2498243E11
Primary
Approved
8307
KETOPROFEN

Approved Use

Ketoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea.

Launch Date

7.2489599E11
Primary
Approved
8307
KETOPROFEN

Approved Use

Ketoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea.

Launch Date

7.2489599E11
Primary
Approved
8307
KETOPROFEN

Approved Use

Ketoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea.

Launch Date

7.2489599E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.1 μg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7439263
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
21.91 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7439263
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.13 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7439263
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETOPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
12.5 mg single, oral
Dose: 12.5 mg
Route: oral
Route: single
Dose: 12.5 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf
Page: p. 34
unhealthy, 36.8 years (range: 18 - 65 years)
n = 90
Health Status: unhealthy
Age Group: 36.8 years (range: 18 - 65 years)
Sex: M+F
Population Size: 90
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf
Page: p. 34
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (mild, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf
Page: p. 34
2400 mg single, oral
Overdose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf
unhealthy, 45 years
Health Status: unhealthy
Age Group: 45 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf
Other AEs: Epigastric pain...
Other AEs:
Epigastric pain (mild, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf
100 mg 1 times / day multiple, topical
Dose: 100 mg, 1 times / day
Route: topical
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16078335/
unhealthy, adult
n = 172
Health Status: unhealthy
Condition: tendinitis
Age Group: adult
Population Size: 172
Sources:
https://pubmed.ncbi.nlm.nih.gov/16078335/
Sources:
https://pubmed.ncbi.nlm.nih.gov/16078335/
100 ug 3 times / day steady, oral (max)
Dose: 100 ug, 3 times / day
Route: oral
Route: steady
Dose: 100 ug, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
unhealthy
n = 50
Health Status: unhealthy
Condition: Lymphedema
Population Size: 50
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
Other AEs: Cellulitis...
Other AEs:
Cellulitis (below serious, 3 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
75 ug 3 times / day steady, oral
Dose: 75 ug, 3 times / day
Route: oral
Route: steady
Dose: 75 ug, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
unhealthy
n = 19
Health Status: unhealthy
Condition: Lymphedema
Population Size: 19
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
Other AEs: Rash...
Other AEs:
Rash (below serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
75 ug 3 times / day steady, oral
Dose: 75 ug, 3 times / day
Route: oral
Route: steady
Dose: 75 ug, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
unhealthy
n = 23
Health Status: unhealthy
Condition: Lymphedema
Population Size: 23
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
Other AEs: Cellulitis...
Other AEs:
Cellulitis (below serious, 1 patient)
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
AEs

AEs

AESignificanceDosePopulation
Rash mild, 1 patient
Disc. AE
12.5 mg single, oral
Dose: 12.5 mg
Route: oral
Route: single
Dose: 12.5 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf
Page: p. 34
unhealthy, 36.8 years (range: 18 - 65 years)
n = 90
Health Status: unhealthy
Age Group: 36.8 years (range: 18 - 65 years)
Sex: M+F
Population Size: 90
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf
Page: p. 34
Epigastric pain mild, 1 patient
2400 mg single, oral
Overdose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf
unhealthy, 45 years
Health Status: unhealthy
Age Group: 45 years
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf
Cellulitis below serious, 3 patients
100 ug 3 times / day steady, oral (max)
Dose: 100 ug, 3 times / day
Route: oral
Route: steady
Dose: 100 ug, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
unhealthy
n = 50
Health Status: unhealthy
Condition: Lymphedema
Population Size: 50
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
Rash below serious, 1 patient
75 ug 3 times / day steady, oral
Dose: 75 ug, 3 times / day
Route: oral
Route: steady
Dose: 75 ug, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
unhealthy
n = 19
Health Status: unhealthy
Condition: Lymphedema
Population Size: 19
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
Cellulitis below serious, 1 patient
75 ug 3 times / day steady, oral
Dose: 75 ug, 3 times / day
Route: oral
Route: steady
Dose: 75 ug, 3 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
unhealthy
n = 23
Health Status: unhealthy
Condition: Lymphedema
Population Size: 23
Sources:
https://clinicaltrials.gov/ct2/show/NCT02257970
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OAT1
584

OAT2
144

OAT3
625

OAT4
145

MRP2
363

MRP4
202
CYP
252

UGT1A1
417

UGT1A3
421

UGT1A9
378

UGT2B4
248

UGT2B7
387
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OAT1
588
 yes [IC50 1.3 uM]
MRP2
452
 yes [IC50 1.4 uM]
MRP4
235
 yes [IC50 11.9 uM]
OAT2
146
 yes [IC50 400 uM]
OAT3
627
 yes [IC50 5.98 uM]
OAT4
145
 yes [IC50 70.3 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
252
 minor
UGT2B4
248
 no
UGT1A1
417
 yes
UGT1A3
421
 yes
UGT1A9
378
 yes
UGT2B7
387
 yes
PubMed

PubMed

TitleDatePubMed
Modeling cyclooxygenase inhibition. Implication of active site hydration on the selectivity of ketoprofen analogues.
2000 Jun 1
Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs.
2001
Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease.
2001
Use of continuous fluid drainage for severe polyhydramnios due to twin to twin transfusion syndrome.
2001
[Two complex suicidal poisonings with drugs and their medicolegal aspects].
2001
Early-morning administration of dexketoprofen-trometamol in morning stiffness induced by nodal osteoarthritis of the hands.
2001
Release behavior of ketoprofen from poly(acryloyl-L-proline methyl ester) gels having different crosslinked networks.
2001
Overdose of ketoprofen could be dangerous.
2001 Apr
Interaction between the antinociceptive effect of ketoprofen and adrenergic modulatory systems.
2001 Aug
Simultaneous optimization based on artificial neural networks in ketoprofen hydrogel formula containing O-ethyl-3-butylcyclohexanol as percutaneous absorption enhancer.
2001 Aug
Binding constant determination of drugs toward subdomain IIIA of human serum albumin by near-infrared dye-displacement capillary electrophoresis.
2001 Aug
Investigation of the utility of an in vitro release test for optimizing semisolid dosage forms.
2001 Aug
Sustained release ketoprofen microparticles with ethylcellulose and carboxymethylethylcellulose.
2001 Aug 10
In vitro distribution of ketoprofen enantiomers in articular tissues of osteoarthritic patients.
2001 Dec
Oral ketoprofen in children--could it have been done differently?
2001 Jan
Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain.
2001 Jul
Comparison of tissue concentrations after intramuscular and topical administration of ketoprofen.
2001 Jul
[Enantiomeric separation of drugs based on macrocyclic antibiotics].
2001 Jul
Analgesic profile of peroral and topical ketoprofen upon low pH-induced muscle pain.
2001 Jul
Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate.
2001 Jul
Evaluation of percutaneous absorption and skin irritation of ketoprofen through rat skin: in vitro and in vivo study.
2001 Jul 17
Stereoselective pharmacokinetics of ketoprofen in llamas following intravenous administration.
2001 Jun
Enantiospecific pharmacokinetics of ketoprofen in plasma and synovial fluid of horses with acute synovitis.
2001 Jun
Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery.
2001 Jun
Simultaneous photocontact sensitivity to ketoprofen and oxybenzone.
2001 Jun
Simultaneous determination of loxoprofen and its diastereomeric alcohol metabolites in human plasma and urine by a simple HPLC-UV detection method.
2001 Jun
[Acute pancreatitis and ketoprofen].
2001 Jun-Jul
[Ketoprofen-induced acute hepatitis].
2001 Jun-Jul
I.v. ketoprofen for analgesia after tonsillectomy: comparison of pre- and post-operative administration.
2001 Mar
Thoracoscopy as a nonpharmacotherapeutic research modification for limiting postoperative chest pain.
2001 Mar-Apr
Effect of oxidative stress on the structure and function of human serum albumin.
2001 May
Chiral resolution of flurbiprofen and ketoprofen enantiomers by HPLC on a glycopeptide-type column chiral stationary phase.
2001 May
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.
2001 May-Jun
Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain.
2001 Nov
Measurement of ketoprofen in horse urine using gas chromatography-mass spectrometry.
2001 Oct
Influence of betacyclodextrin on the release of poorly soluble drugs from inert and hydrophilic heterogeneous polymeric matrices.
2001 Oct
Lipopolysaccharide-induced increase of prostaglandin E(2) is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase.
2001 Oct 1
Effects of diclofenac and ketoprofen on nerve conduction velocity in experimental nerve root compression.
2001 Oct 15
Optimized conditions of bio-mimetic artificial membrane permeation assay.
2001 Oct 9
Transdermal delivery of ketoprofen using microemulsions.
2001 Oct 9
[ Ambulatory laparoscopic gynecological surgery in Africa: feasibility].
2001 Sep
Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study.
2001 Sep
Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin.
2001 Sep
Promoting mechanism of menthol derivative, 1-O-ethyl-3-buthylcyclohexanol, on the percutaneous absorption of ketoprofen.
2001 Sep
Incompatibility of prochlorperizine and ketoprofen.
2001 Sep
Photocontact dermatitis to ketoprofen.
2001 Sep
Antihyperalgesic effects of the muscarinic receptor ligand vedaclidine in models involving central sensitization in rats.
2001 Sep
Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells.
2001 Sep
In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac.
2001 Sep
Enhancement of the activity of doxorubicin by inhibition of glutamate transporter.
2001 Sep 15
Patents

Patents

04278802
6
04340740
10
JP2000212078A
6
JP2001503372A
27
JP2002541233A
392
JP2004269528A
28
JP2004523497A
78
JP2004534728A
75
JP2005539013A
22
JP2007506774A
21
JP2007508039A
109
JP2008504356A
31
JP2008536574A
19
JP2009526755A
434
JP2011500184A
34
JP2011529101A
66
JP4701159B2
69
JP4758474B2
84
JP4790950B2
20
JP4851943B2
41
JPH026432A
6
JPH0331221A
6
JPH05262697A
6
JPH0648958A
7
JPH0840880A
6
JPH0952825A
11
JPH0987170A
6
JPH0987171A
6
JPH10298065A
6
JPH1072343A
6
JPH1129496A
6
JPS5536450A
6
JPS5810517A
6
JPS59122422A
6
JPS61238724A
6
JPS62298526A
7
JPS63313581A
6
JPS6425719A
6

Sample Use Guides

In Vivo Use Guide
intravenous: 0,5 mg/kg up to 50 mg oral: 5 - 100 mg
Route of Administration: Other
In Vitro Use Guide
Curator's Comment: In cultivation of freshly isolated epidermal cells, 5 mM Ketoprofen inhibited the culture-promoted expression of PCl-augmented expression of major histocompatibility complex class II and CD86 on Langerhans cells
Male Sprague-Dawley rats (180–230 g) were killed by ether anesthesia, and brains without cerebellum were rapidly excised. Organs were washed in icecold saline and then cut into small tissue fragments (about 1–3 mm^3). Fragments of one-half of the brain (500 mg) were incubated in 3.0 ml of oxygenated Tyrode solution (pH 7.4) at 37°C for 10 min in the presence of the inhibitor (Dexketoprofen 4-1000nM) or vehicle. Incubations were terminated by brief centrifugation to remove tissue fragments. The resulting supernatants were stored at −80°C until levels of PGF2a were determined by a specific competitive enzyme immunoassay
Substance Class Chemical
Created
by admin
on Fri Dec 16 21:51:42 UTC 2022
Edited
by admin
on Fri Dec 16 21:51:42 UTC 2022
Record UNII
90Y4QC304K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
KETOPROFEN
EP   GREEN BOOK   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
R.P. 19,583
Code English
(RS)-KETOPROFEN
Common Name English
RU-4733
Code English
KETOPROFEN [MART.]
Common Name English
ISO-K
Brand Name English
KETOPROFEN [VANDF]
Common Name English
R.P. 19583
Code English
SECTOR
Brand Name English
ORUVAIL
Brand Name English
ALRHEUMAT
Brand Name English
RP-19583
Code English
ketoprofen [INN]
Common Name English
BENZENEACETIC ACID, 3-BENZOYL-.ALPHA.-METHYL-
Systematic Name English
ORUDIS
Brand Name English
KETOPROFEN [USP MONOGRAPH]
Common Name English
(±)-M-BENZOYLHYDRATROPIC ACID
Systematic Name English
IDEA-033
Code English
NSC-758144
Code English
(±)-KETOPROFEN
Common Name English
ANEOL
Brand Name English
HYDRATROPIC ACID, M-BENZOYL-
Common Name English
KETOPROFEN [JAN]
Common Name English
(±)-3-BENZOYL-.ALPHA.-METHYLBENZENEACETIC ACID
Systematic Name English
KETORIN
Brand Name English
KETOPROFEN [GREEN BOOK]
Common Name English
KETOPROFEN [MI]
Common Name English
KETOPROFEN [EP IMPURITY]
Common Name English
KETOPROFEN [USAN]
Common Name English
CAPISTEN
Brand Name English
KETOPROFEN [ORANGE BOOK]
Common Name English
ACTRON
Brand Name English
Ketoprofen [WHO-DD]
Common Name English
NEXCEDE
Brand Name English
KETOPROFEN [EP MONOGRAPH]
Common Name English
19583RP
Code English
KETOPROFEN [USP IMPURITY]
Common Name English
ACTRON KETOPROFEN
Brand Name English
Classification Tree Code System Code
WHO-ATC M01AE03
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
WHO-VATC QM01AE53
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
WHO-VATC QM01AE03
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
NDF-RT N0000175722
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
LIVERTOX NBK548678
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
NDF-RT N0000175721
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
WHO-ATC M02AA10
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
NCI_THESAURUS C257
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
NDF-RT N0000000160
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
WHO-VATC QM02AA10
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
CFR 21 CFR 522.1225
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
WHO-ATC M01AE53
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
Code System Code Type Description
CHEBI
6128
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
INN
3284
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
WIKIPEDIA
KETOPROFEN
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
PUBCHEM
3825
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
FDA UNII
90Y4QC304K
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
CAS
172964-50-0
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
SUPERSEDED
EVMPD
SUB08374MIG
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
MERCK INDEX
M6622
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY Merck Index
LACTMED
Ketoprofen
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
DRUG CENTRAL
1528
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
CAS
22161-86-0
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
SUPERSEDED
NSC
758144
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
NCI_THESAURUS
C47578
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
DAILYMED
90Y4QC304K
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
ChEMBL
CHEMBL571
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
ECHA (EC/EINECS)
244-759-8
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
RXCUI
6142
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY RxNorm
CAS
22071-15-4
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
CAS
154907-35-4
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
SUPERSEDED
DRUG BANK
DB01009
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
MESH
D007660
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
RS_ITEM_NUM
1356632
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
EPA CompTox
DTXSID6020771
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
IUPHAR
4795
Created by admin on Fri Dec 16 21:51:42 UTC 2022 , Edited by admin on Fri Dec 16 21:51:42 UTC 2022
PRIMARY
Related Record Type Details
OAT-3
TRANSPORTER -> INHIBITOR
OAT-4
TRANSPORTER -> INHIBITOR
Structure of KETOPROFEN, (R)-
ENANTIOMER -> RACEMATE
OAT-1
TRANSPORTER -> INHIBITOR
Structure of DEXKETOPROFEN
ENANTIOMER -> RACEMATE
Structure of KETOPROFEN SODIUM
SALT/SOLVATE -> PARENT
Structure of KETOPROFEN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of KETOPROFEN ARGININE
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of KETOPROFEN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
OAT-2
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of 3-(CYANOMETHYL)BENZOIC ACID
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 2-(3-BENZOYLPHENYL)PROPIONITRILE
IMPURITY -> PARENT
Structure of 2-(3-(2,4,5-TRIMETHYLBENZOYL)PHENYL)PROPANOIC ACID, (±)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 3-ACETYLBENZOPHENONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-(1-CYANOETHYL)BENZOIC ACID
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of KETOPROFEN AMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-(3-(4-METHYLBENZOYL)PHENYL)PROPANOIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of (3-BENZOYLPHENYL)ACETIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-(1-CARBOXYETHYL)BENZOIC ACID, (±)-
IMPURITY -> PARENT
Structure of 3-ACETYLBENZOPHENONE
IMPURITY -> PARENT
Structure of 2-(3-(4-METHYLBENZOYL)PHENYL)PROPANOIC ACID
IMPURITY -> PARENT
2-(3-(2(5),3,4-TRIMETHYLBENZOYL)PHENYL)PROPANOIC ACID, (±)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 2-(3-(2,4-DIMETHYLBENZOYL)PHENYL)PROPANOIC ACID, (±)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of (3-BENZOYLPHENYL)ETHANENITRILE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 3-BENZOYLBENZOIC ACID
IMPURITY -> PARENT
Structure of 3-(1-CARBOXYETHYL)BENZOIC ACID, (±)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL-2-(3-BENZOYLPHENYL)PROPANOATE, (S)-
IMPURITY -> PARENT
Structure of 2-(3-BENZOYLPHENYL)PROPIONITRILE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of KETOPROFEN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966